Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 411 participants.
Also called NCT01375777
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 411 participants
- Sponsor
- Registry
-
NCT01375777
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, Denmark
- Registry status
- Completed
Technical summary
Registry record NCT01375777. Randomized; quadruple masking; primary purpose treatment. Start 2011-07-06 (actual); primary completion 2012-03-02 (actual). Results posted on 2015-10-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
- Acronym
- MENDEL
- Condition
- Hyperlipidemia
- Intervention (Biological)
- Evolocumab
- Intervention (Drug)
- Ezetimibe
- Intervention (Other)
- Placebo to Evolocumab
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01375777- Content hash
d1e2a05e8f222f23af1c592b66e2a9f129f61c662d733d16ade60f4d9a401bbe